SAN DIEGO, April 14, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Actinium Pharmaceuticals, Inc. (NYSE: ATNM) securities between October 31, 2022 and August 2, 2024. Actinium is a late-stage biopharmaceutical company that develops targeted radiotherapies, such as Iomab-B, to treat people who have failed existing oncology therapies. For more information, submit a form, email attorney

Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational diabetes. G7 15 Day, scheduled to launch in the second half of this year, will have a 15.5-day wear time (including a 12-hour grace period) and last 15% longer than Dexcom G7, according to the company. The new system sends real-time glucose information to the Dexcom G7 app or receiver every five minutes

CAMBRIDGE, Mass., April 14, 2025 /PRNewswire/ -- The Gates Medical Research Institute (Gates MRI) today announced the appointment of Alexander Schmidt, MD, PhD, as Chief Medical Officer (CMO) and Head of Development, effective April 1, 2025. He has been serving as interim CMO and Head of Development since January 1, 2025. Continue Reading Alexander Schmidt, Chief Medical Officer and Head of Development, Gates Medical Research Institute Dr. Schmidt joined the Gates MRI in 2018 as Head of Transla

The White House Office of Management and Budget (OMB) released two memos directed to the heads of all executive branch departments and agencies establishing policies on federal AI use and purchase of AI in government. The memos, which align with an Executive Order President Donald Trump signed in January, replace former President Joe Biden's previous guidance (M-24-10 and M-24-18) but maintain some of the same recommendations. The first memo (M-25-21) directs agencies to "lessen the burden of

National Law Firm Filed One of the First Eye Injury Cases against Novo Nordisk in the Superior Court of New Jersey, Middlesex County PORT WASHINGTON, N.Y., April 14, 2025 /PRNewswire/ -- Parker Waichman LLP, a nationally recognized law firm dedicated to representing victims of defective drugs and devices, recently filed a lawsuit against Novo Nordisk on behalf of a New Jersey based Plaintiff diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION). NAION, a debilitating eye condi

Seized counterfeit Ozempic® (semaglutide) injection 1 mg distributed outside the Novo Nordisk authorized supply chain Visual examination of seized product contains counterfeit features; product composition has not been conclusively determined at this time US Food and Drug Administration (FDA) seized counterfeit Ozempic® and Novo Nordisk is assisting with the investigation PLAINSBORO, N.J., April 14, 2025 /PRNewswire/ -- Novo Nordisk has become aware of several hundred units of Ozempic® (sem

April 14, 2025Announcement no. 10 THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE A PROSPECTUS OR A PUBLIC OFFER OF THE SECURITIES DESCRIBED HEREIN NOR IS IT AN OFFER TO SELL OR ISSUE, OR A SOLICITATION

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, April 14, 2025 /PRNewswire/ -- Equity Insider News Commentary – Routine medical appointments or cancer screenings—critical for catching the disease in earlier, more treatable stages—has dropped to just over 50% of the population. At the same time, doctors are raising alarm bells over a noticeable increase in cancer diagnoses among younger adults, especially women. With proposed funding cuts to the NIH now

NANJING, China, April 15, 2025 /PRNewswire/ -- ProBio, a global leader in the antibody discovery and development, is pleased to announce its upcoming poster presentation at the American Association for Cancer ResearchⓇ (AACR) 116th Annual Meeting, to be held April 25 to 30, 2025, at the McCormick Place Convention Center in Chicago, Illinois. Continue Reading "We are excited to present our pre-clinical findings at the AACR, showcasing the significant potential of our CD3 agonistic single-domain a

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules – corrected: reference to date of product launch in Europe removed; link to “Important Safety Information” updated Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling inflammatory diseasesDespite FDA approval nearly a decade ago, etanercept biosimilar continues to be blockedSandoz seeking damages in addition to clearing path for launch Basel, April 14,